Inobrodib is under clinical development by CellCentric and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Inobrodib’s likelihood of approval (LoA) and phase transition for Myelodysplastic Syndrome took place on 28 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 28 Jul 2022 increased Inobrodib’s LoA and PTSR for Non-Hodgkin Lymphoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Inobrodib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Inobrodib overview

Inobrodib (CCS-1477) is under development for the treatment of solid tumors including castrate-resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer, hematological cancers including diffuse large B-Cell lymphoma, relapsed or refractory multiple myeloma, acute myeloid leukaemia, non-hodgkin lymphoma, myelodysplastic syndrome, lung cancer and bladder cancer. It is administered orally. The drug candidate acts by targeting E1A binding protein (p300) and CREB binding protein (CBP). p300/CBP collectively relates to histone acetyl transferase proteins.

CellCentric overview

CellCentric is a clinical stage biotechnology company that develops novel small molecule inhibitors. The company develops CCS1477, a small molecule inhibitors against a histone acetyl transferase complex for the treatment of the form of prostate cancer and for lung and bladder cancer. It conducts clinical program which has clinical utility in other cancers including non-small cell lung, breast and colon cancer. Its CCS1477 can also be used as a monotherapy and in combination with other drugs. The company operates through its offices located in Oxford and Cheshire, the UK. CellCentric is headquartered in Cambridge, the UK.

Quick View Inobrodib LOA Data

Report Segments
  • Innovator
Drug Name
  • Inobrodib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: CellCentric
  • Originator: CellCentric
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.